Navigating the Changing Landscape of Relapsed/Refractory Multiple Myeloma: Optimizing Treatment Strategies : Episode 8
Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
Dr Nadeem discusses his approach to sequencing bispecifics vs chimeric antigen receptor T-cell therapies, including B-cell maturation antigen (BCMA) and non-BCMA bispecifics, and the factors he considers, followed by key takeaways from a recent meeting on bispecifics in relapsed/refractory multiple myeloma, focusing on dosing, adverse event management, and clinical pearls for oncologists.
EP: 1.R/R MM: Treating Patients with CNS Metastases Involvement
EP: 2.Optimal Dosing Strategies and Managing AEs
EP: 3.R/R MM: Bispecifics in R/R MM: Key Takeaways
EP: 4.R/R MM: Insights Into Optimal Dosing for Bispecifics
EP: 5.Bispecifics in R/R MM: AE Management and Sequencing
EP: 6.Future Perspectives in R/R MM
EP: 7.R/R MM Treatment Landscape: Role of Bispecifics
Now Viewing
EP: 8.Clinical Pearls Surrounding the Use of Bispecifics in R/R MM
Video content above is prompted by the following
- How do you approach sequencing (bispecifics vs chimeric antigen receptor T-cell or B-cell maturation antigen [BCMA] bispecific vs non-BCMA bispecific) in your practice?
- What factors do you consider?
- Please share your key takeaways from that meeting, especially surrounding the use of bispecifics (dosing, adverse event management) in relapsed/refractor multiple myeloma (R/R MM).
- What clinical pearls can you share with fellow medical oncologists considering the use of bispecifics in R/R MM?
Recent Videos
Related Content
